Celecoxib

Drug Profile

Celecoxib

Alternative Names: Celebra; Celebrex; Celecox; Niflam; Onsenal; SC-58635; YM-177

Latest Information Update: 23 Nov 2016

Price : $50

At a glance

  • Originator Pfizer
  • Developer Astellas Pharma; Dana-Farber Cancer Institute; Department of Veterans Affairs; Linkoping University Hospital; Pfizer; Swedish Lung Cancer Study Group; University of Connecticut; Zydus Cadila
  • Class Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pyrazoles; Small molecules; Sulfonamides
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Familial adenomatous polyposis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute pain; Ankylosing spondylitis; Back pain; Cervicobrachial syndrome; Dental pain; Dysmenorrhoea; Familial adenomatous polyposis; Juvenile rheumatoid arthritis; Osteoarthritis; Pain; Periarthritis; Postoperative pain; Rheumatic disorders; Rheumatoid arthritis; Tendinitis; Tenosynovitis
  • Phase III Non-small cell lung cancer
  • Phase II Stomatitis
  • Discontinued Alzheimer's disease; Bladder cancer; Gouty arthritis; Prostate cancer

Most Recent Events

  • 13 Nov 2016 Top-line efficacy data from the phase IV PRECISION trial in Rheumatic arthritis released by Pfizer
  • 15 Mar 2016 Biomarkers information updated
  • 28 Oct 2015 Discontinued - Preregistration for Pain (Monotherapy) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top